Biomedical research at Oslo University Hospital
Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.
Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.
Click here to see hierarchical division and subunit overview
Summary of publications:
Publications (original articles or review articles) published in 2018 from OUS - The Lipid Clinic
14 publications found
Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial
J Clin Lipidol, 13 (1), 138-147
DOI 10.1016/j.jacl.2018.11.007, PubMed 30591415
Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program
Atherosclerosis, 278, 307-314
DOI 10.1016/j.atherosclerosis.2018.08.036, PubMed 30293878
Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study
J Clin Lipidol, 12 (5), 1199-1207
DOI 10.1016/j.jacl.2018.05.007, PubMed 30318065
Sex differences in cholesterol levels from birth to 19 years of age may lead to increased cholesterol burden in females with FH
J Clin Lipidol, 12 (3), 748-755.e2
DOI 10.1016/j.jacl.2018.02.021, PubMed 29609857
Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia
J Clin Lipidol, 12 (6), 1463-1470
DOI 10.1016/j.jacl.2018.08.011, PubMed 30287210
Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia
Stroke, 50 (1), 172-174
DOI 10.1161/STROKEAHA.118.023456, PubMed 30580708
Are PCSK9 Inhibitors Cost Effective?
Pharmacoeconomics, 36 (9), 1031-1041
DOI 10.1007/s40273-018-0671-0, PubMed 29777433
Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)
Am J Cardiol, 121 (8), 940-948
DOI 10.1016/j.amjcard.2017.12.040, PubMed 29472008
Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia
Heart, 104 (19), 1600-1607
DOI 10.1136/heartjnl-2017-312706, PubMed 29622598
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230
Effect of low carbohydrate high fat diet on LDL cholesterol and gene expression in normal-weight, young adults: A randomized controlled study
Atherosclerosis, 279, 52-61
DOI 10.1016/j.atherosclerosis.2018.10.013, PubMed 30408717
Evaluation of a short Food Frequency Questionnaire to assess cardiovascular disease-related diet and lifestyle factors
Food Nutr Res, 62
DOI 10.29219/fnr.v62.1370, PubMed 29720928
A randomized controlled trial in Norwegian pharmacies on effects of risk alert and advice in people with elevated cardiovascular risk
Prev Med Rep, 12, 79-86
DOI 10.1016/j.pmedr.2018.08.004, PubMed 30191097
Familial hypercholesterolemia and young patients' thoughts on own condition and treatment
Patient Educ Couns, 102 (5), 1005-1012
DOI 10.1016/j.pec.2018.12.025, PubMed 30606641